## Louise Birkedal GlenthÃ,j

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8914834/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Predictors of remission from the ultraâ€high risk state for psychosis. Microbial Biotechnology, 2021, 15, 104-112.	0.9	8
2	EPA guidance on treatment of negative symptoms in schizophrenia. European Psychiatry, 2021, 64, e21.	0.1	70
3	Obsessive-Compulsive Symptoms and Other Symptoms of the At-risk Mental State for Psychosis: A Network Perspective. Schizophrenia Bulletin, 2021, 47, 1018-1028.	2.3	10
4	Association of Structural Magnetic Resonance Imaging Measures With Psychosis Onset in Individuals at Clinical High Risk for Developing Psychosis. JAMA Psychiatry, 2021, 78, 753.	6.0	74
5	Global fractional anisotropy predicts transition to psychosis after 12Âmonths in individuals at ultraâ€high risk for psychosis. Acta Psychiatrica Scandinavica, 2021, 144, 448-463.	2.2	9
6	Changes in negative symptoms are linked to white matter changes in superior longitudinal fasciculus in individuals at ultra-high risk for psychosis. Schizophrenia Research, 2021, 237, 192-201.	1.1	6
7	EPA guidance on assessment of negative symptoms in schizophrenia. European Psychiatry, 2021, 64, e23.	0.1	94
8	Assessing social skills in individuals at ultra-high risk for psychosis: Validation of the High Risk Social Challenge task (HiSoC). Schizophrenia Research, 2020, 215, 365-370.	1.1	7
9	Basic symptoms influence realâ€life functioning and symptoms in individuals at high risk for psychosis. Acta Psychiatrica Scandinavica, 2020, 141, 231-240.	2.2	7
10	Supplementary data for a focused review and meta-analysis of 1H-MRS studies on cerebral glutamate and GABA levels in high-risk of psychosis states. Data in Brief, 2020, 28, 104920.	0.5	1
11	Cerebral glutamate and GABA levels in high-risk of psychosis states: AÂfocused review and meta-analysis of 1H-MRS studies. Schizophrenia Research, 2020, 215, 38-48.	1.1	36
12	Cerebral Glutamate and Gamma-Aminobutyric Acid Levels in Individuals at Ultra-high Risk for Psychosis and the Association With Clinical Symptoms and Cognition. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 569-579.	1.1	12
13	Investigating Cognitive and Clinical Predictors of Real-Life Functioning, Functional Capacity, and Quality of Life in Individuals at Ultra-High Risk for Psychosis. Schizophrenia Bulletin Open, 2020, 1, .	0.9	5
14	Effectiveness of cognitive remediation in the ultraâ€high risk state for psychosis. World Psychiatry, 2020, 19, 401-402.	4.8	18
15	Cognitive remediation plus standard treatment versus standard treatment alone for individuals at ultra-high risk of developing psychosis: Results of the FOCUS randomised clinical trial. Schizophrenia Research, 2020, 224, 151-158.	1.1	23
16	No Effects of Cognitive Remediation on Cerebral White Matter in Individuals at Ultra-High Risk for Psychosis—A Randomized Clinical Trial. Frontiers in Psychiatry, 2020, 11, 873.	1.3	9
17	Baseline measures of cerebral glutamate and GABA levels in individuals at ultrahigh risk for psychosis: Implications for clinical outcome after 12Âmonths. European Psychiatry, 2020, 63, e83.	0.1	7
18	Self-perceived cognitive impairments in psychosis ultra-high risk individuals: associations with objective cognitive deficits and functioning. NPJ Schizophrenia, 2020, 6, 31.	2.0	5

#	Article	IF	CITATIONS
19	Development of Executive Functions as Reflected in Daily Life Behaviors in Young Adults at Ultra-High Risk for Psychosis: Associations With Symptoms and Functioning. Schizophrenia Bulletin Open, 2020, 1,	0.9	1
20	Experiential negative symptoms are more predictive of real-life functional outcome than expressive negative symptoms in clinical high-risk states. Schizophrenia Research, 2020, 218, 151-156.	1.1	19
21	Widespread higher fractional anisotropy associates to better cognitive functions in individuals at ultraâ€high risk for psychosis. Human Brain Mapping, 2019, 40, 5185-5201.	1.9	22
22	Emotion recognition latency, but not accuracy, relates to real life functioning in individuals at ultra-high risk for psychosis. Schizophrenia Research, 2019, 210, 197-202.	1.1	13
23	Validation of the MUSIC Model of Motivation Inventory for use with cognitive training for schizophrenia spectrum disorders: A multinational study. Schizophrenia Research, 2019, 206, 142-148.	1.1	5
24	Non-pharmacological modulation of cerebral white matter organization: A systematic review of non-psychiatric and psychiatric studies. Neuroscience and Biobehavioral Reviews, 2018, 88, 84-97.	2.9	13
25	Examining speed of processing of facial emotion recognition in individuals at ultra-high risk for psychosis: Associations with symptoms and cognition. Schizophrenia Research, 2018, 195, 562-563.	1.1	5
26	White matter maturation during 12 months in individuals at ultraâ€highâ€risk for psychosis. Acta Psychiatrica Scandinavica, 2018, 137, 65-78.	2.2	23
27	The effect of cognitive remediation in individuals at ultra-high risk for psychosis: a systematic review. NPJ Schizophrenia, 2017, 3, 20.	2.0	62
28	Negative symptoms mediate the relationship between neurocognition and function in individuals at ultrahigh risk for psychosis. Acta Psychiatrica Scandinavica, 2017, 135, 250-258.	2.2	25
29	Course of illness in a sample of patients diagnosed with a schizotypal disorder and treated in a specialized early intervention setting. Findings from the 3.5 year follow-up of the OPUS II study. Schizophrenia Research, 2017, 182, 24-30.	1.1	16
30	Social cognition in patients at ultra-high risk for psychosis: What is the relation to social skills and functioning?. Schizophrenia Research: Cognition, 2016, 5, 21-27.	0.7	46
31	The FOCUS trial: cognitive remediation plus standard treatment versus standard treatment for patients at ultra-high risk for psychosis: study protocol for a randomised controlled trial. Trials, 2015, 16, 25.	0.7	40